Surgical staging for patients presenting with grade 1 endometrial carcinoma

被引:129
作者
Ben-Shachar, I
Pavelka, J
Cohn, DE
Copeland, LJ
Ramirez, N
Manolitsas, T
Fowler, JM
机构
[1] Ohio State Univ, Coll Med & Publ Hlth, Dept Pathol, Arthur G James Canc Hosp, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med & Publ Hlth, Solove Res Inst, Columbus, OH 43210 USA
[3] Ohio State Univ, Coll Med & Publ Hlth, Div Gynecol Oncol, Dept Obstet & Gynecol, Columbus, OH 43210 USA
关键词
D O I
10.1097/01.AOG.0000149151.74863.c4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To examine the impact of surgical staging of patients presenting with grade 1 endometrial cancer. METHODS: The charts of all patients who presented for surgery for endometrial cancer between March 1997 and July 2003 were analyzed for demographic data, final tumor histology, grade, stage, and complications. RESULTS: A total of 349 patients underwent surgical management for endometrial cancer. Preoperatively, 181 (52%) were identified with grade 1 disease, with a mean age of 61 years (range 27-89). Surgical staging (pelvic para-aortic lymphadenectomy) was performed in 82% of cases and was omitted only in cases when disease was apparently confined to the endometrium and surgical risk was high. In staged patients, 3.2% had severe surgical complications. There were 2 perioperative mortalities (1 pulmonary emboli and 1 myocardial infarct). In comparison of pre- and postoperative histology, 19% of patients were upgraded, with 15% grade 2, 0.5% grade 3, 2.5% serous or clear cell, and 1% mixed mesodermal tumor. Lymph node metastases were found in 3.9% of patients presenting with grade 1 endometrial cancer, and 10.5% had extrauterine spread (> IIb). High-risk uterine features, including myometrial invasion more than 1/2, grade 3 lesions, high-risk histologic variants, and/or cervical involvement, were found in 26% of the patients. No patients with stage Ia-IIb endometrioid cancer received adjuvant teletherapy or chemotherapy. Four patients with low-risk uterine features were found to have extrauterine disease. Twelve percent of patients received adjuvant therapy, and 17% avoided teletherapy and/or chemotherapy based on surgical staging. CONCLUSION: Surgical staging in patients presenting with grade 1 endometrial cancer significantly impacted postoperative treatment decisions in 29% of patients. Omitting lymphadenectorny in patients presenting with grade 1 endometrial cancer may lead to inappropriate postoperative management. (C) 2005 by The American College of Obstetricians and Gynecologists.
引用
收藏
页码:487 / 493
页数:7
相关论文
共 39 条
  • [1] ABELER VM, 1991, CANCER, V67, P3093, DOI 10.1002/1097-0142(19910615)67:12<3093::AID-CNCR2820671226>3.0.CO
  • [2] 2-L
  • [3] Endometrial carcinoma - Relative effectiveness of adjuvant irradiation vs therapy reserved for relapse
    Ackerman, I
    Malone, S
    Thomas, G
    Franssen, E
    Balogh, J
    Dembo, A
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 60 (02) : 177 - 183
  • [4] A comparison of treatment strategies for endometrial adenocarcinoma: Analysis of financial impact
    Barnes, MN
    Roland, PY
    Straughn, M
    Kilgore, LC
    Alvarez, RD
    Partridge, EE
    [J]. GYNECOLOGIC ONCOLOGY, 1999, 74 (03) : 443 - 447
  • [5] LAPAROSCOPIC STAGING OF THE PATIENT WITH INCOMPLETELY STAGED EARLY ADENOCARCINOMA OF THE ENDOMETRIUM
    CHILDERS, JM
    SPIRTOS, NM
    BRAINARD, P
    SURWIT, EA
    [J]. OBSTETRICS AND GYNECOLOGY, 1994, 83 (04) : 597 - 600
  • [6] CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
  • [7] 2-8
  • [8] The morbidity of treatment for patients with stage I endometrial cancer:: Results from a randomized trial
    Creutzberg, CL
    van Putten, WLJ
    Koper, PC
    Lybeert, MLM
    Jobsen, JJ
    Wárlám-Rodenhuis, CC
    De Winter, KAJ
    Lutgens, LCHW
    van den Bergh, ACM
    van der Steen-Banasik, E
    Beerman, H
    van Lent, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (05): : 1246 - 1255
  • [9] DANIEL AG, 1988, OBSTET GYNECOL, V71, P612
  • [10] Dijkhuizen FPHLJ, 2000, CANCER, V89, P1765, DOI 10.1002/1097-0142(20001015)89:8<1765::AID-CNCR17>3.3.CO